Objective-To determine the efficacy of long-term anti-miR-33 therapy on the progression of atherosclerosis in high-fat, high-cholesterol-fed Ldlr -/-mice.
R ecently, we and others reported on miR-33 (also known as miR-33a or miR-33a-5p), an intragenic miRNA encoded within sterol regulatory element-binding protein 2 (SREBP-2) that modulates the expression of several transmembrane transporters, that include ATP-binding cassette transporter, sub family A, member 1 (ABCA1); ATP-binding cassette transporter, subfamily G, member 1; ATP-binding cassette, sub-family B, member 11; ATPase aminophospholipid transporter, class I, type 8B, member 1. [1] [2] [3] [4] [5] [6] These studies suggested that miR-33 plays important roles in fine-tuning both high-density lipoprotein (HDL) and biliary metabolism. Indeed, we and others showed that short-term silencing of hepatic miR-33 with antisense oligonucleotides increases both HDL-cholesterol (HDL-c) [1] [2] [3] [4] [5] and hepatic bile secretion. 6 Additionally, treatment of mice with anti-miR-33 oligonucleotides led to increased reverse cholesterol transport in vivo. 6, 7 The reverse cholesterol transport pathway mobilizes extrahepatic cholesterol into HDL back to the liver, where both cholesterol and its metabolite bile acids are secreted into bile for final excretion through the feces. Hence, reverse cholesterol transport is regarded as atheroprotective and strategies that promote/accelerate the flow of cholesterol through this pathway, for example, raising HDL levels or promoting hepatobiliary removal of sterols, are predicted to be effective in reducing the risk of cardiovascular disease. 
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Collectively, the initial reports on miR-33 suggested that patients with hypercholesterolemia might benefit from a therapy that incorporated silencing of miR-33 (eg, anti-miR-33 oligonucleotides). In agreement with this idea, Rayner et al reported that anti-miR-33 oligonucleotides were able to increase HDL-c and accelerate the regression of atherosclerotic lesions in hyperlipidemic Ldlr -/-mice switched to standard chow diet. 7 However, no reports are yet available regarding the impact of miR-33 silencing on the progression of atherosclerosis. Hence, our purpose was to determine the efficacy of long-term anti-miR-33 therapy on the development of arterial disease in high-fat, high-cholesterol-fed Ldlr -/-mice.
Materials and Methods
Male, 10-week-old Ldlr -/-mice (Jackson Laboratories) were maintained on a 12 hour/12 hour light/dark cycle with unlimited access to food and water, and injected intraperitoneally with 200 μL saline (n=5), or 7 mg/kg control (5′-TCCTAGAAAGAGTAGA; n=13) or anti-miR-33 (5′-TGCAACTACAATGCA; n=11) locked nucleic acid oligonucleotides (a kind gift from Miragen Therapeutics, Inc) once a week. After 2 weeks on chow, mice were switched to, and maintained on, a western diet (WD) containing 21% fat and 1.25% cholesterol (Research Diets D12108) for 12 weeks. Mice were fasted for 6 hours before euthanization. Detailed materials and methods appear in the online-only Data Supplemental materials.
Results
Anti-miR-33 treatment did not affect body weight ( Figure 1A) , although a trend was observed for accelerated weight gain in the anti-miR-33 group after 10 weeks of treatment. Analysis of plasma samples showed that both total cholesterol and HDL-c increased in the first 2 weeks of treatment with anti-miR-33 oligonucleotides compared with control treatments ( Figure   1B and 1D). These data agree with previous reports [1] [2] [3] 5, 7, 9 and provide evidence that the anti-miR-33 treatment was efficacious. As expected, at the end of the WD feeding, circulating cholesterol levels increased in all animals ( Figure 1C) ; however, no changes in HDL-c were noted between groups ( Figure  1E ). Furthermore, we noted that mice injected with antimiR-33 oligonucleotides showed increased plasma triglycerides (TG), both on chow and after WD ( Figure 1F and 1G). Data Supplement). Concomitant changes in the levels of apolipoprotein A1 and apolipoprotein B48/100 were also noted in these plasma samples ( Figure I in the online-only Data Supplement), further verifying the changes in HDL-c and TG. Collectively, these data suggest that the increase in HDL-c after miR-33 silencing is transient. This is also the first study to report changes in circulating TG after treatment with anti-miR-33 oligonucleotides. These latter results were unexpected, as a previous study showed a decline in plasma VLDL-TG in monkeys receiving anti-miR-33 treatment. 9 One possibility to explain the absence of changes in HDL-c at week 12 in the anti-miR-33 group is that the bioavailability and potency of the oligonucleotides decline over time or in combination with the WD. Additionally, hepatic miR-33 levels are known to decrease in mice fed a WD, 2,3 which might also compromise the success of the antisense treatment. However, RNA and protein analysis of the livers showed that miR-33 was indeed effectively silenced in the anti-miR-33 group, as levels of miR-33 were decreased ≈75%, whereas those of miR-33 targets (ABCA1; ATP-binding cassette, sub-family B, member 11; carnitine palmitoyltransferase 1a) were significantly increased in these mice compared with controls ( Figure  1H and Figure IIA in the online-only Data Supplement). RNA and protein levels of other genes declined or remained unchanged in the same livers ( Figure 1H and Figures I and IIA in the online-only Data Supplement), suggesting that the changes in several miR-33 targets were specific. It is important to stress that the changes in hepatic ABCA1 noted in the livers of anti-miR-33 mice after 12 weeks on WD were not paralleled by increased levels of HDL-c in plasma, as noted above. The reasons behind these latter paradoxical results remain to be elucidated. Further analysis revealed no significant changes in liver weight, and hepatic cholesterol or TG contents ( Figure 1J-1L) . However, hepatic free fatty acid levels were significantly reduced in the anti-miR-33 group ( Figure 1M ). This latter result could be explained by the significant increase in CPT1α or decrease in fatty acid synthase expression in the same livers ( Figure 1H and 1I) . Additionally, we measured the hepatic expression of miRNAs that are known to regulate sterol and TG metabolism. 10 Data in Figure  IIB in the online-only Data Supplement show that miR-378, miR-27a, and miR-122 (but not miR-758, miR-370, miR-335, and miR-125a-5p) were modestly elevated in mice receiving anti-miR-33 treatment. The functional consequences of deregulated expression of these latter miRNAs on TG and sterol homeostasis in mice receiving anti-miR-33 oligonucleotides are unknown. Nevertheless, taken together, the data suggest that the anti-miR-33 oligonucleotides were effective in silencing hepatic miR-33 at the end of the 12 weeks of WD feeding.
Finally, analysis of atherosclerotic lesions both in the aortic root and in en face preparations of the whole aorta revealed no significant differences between groups (Figure 2A-2D) . Likewise, assessment of macrophage and collagen contents in aortic root sections of selected mice in each group with similar lesion sizes revealed no discernible differences between treatments ( Figure 2B ).
Discussion
This is the first report on the impact of long-term antimiR-33 treatment on the progression of atherosclerosis in Ldlr -/-mice. Previous regression studies 7 employed mice that received antimiRs for only 4 weeks, and no data are yet available regarding the continuing efficacy of the oligonucleotides in this regression model. Our data show conclusively that anti-miR-33 oligonucleotides, although effective in suppressing hepatic miR-33 expression and increasing the expression of hepatic miR-33 targets, did not raise HDL-c after mice were switched to the WD and did not provide atheroprotection.
Primates, but not rodents, express a second miR-33 gene (miR-33b) from an intron of SREBP-1. Notably, SREBP-1 and -2 are differentially regulated by hormones, dietary challenges, or statin treatment. In any case, the expression of miR-33a and miR-33b is expected to follow that of their corresponding hosting gene. Whether the 2-nucletide mismatch (outside of the seed sequence) between miR-33a and miR-33b results in differential targeting remains to be established, although studies in human HepG2 cells 11 and in nonhuman primates 9 suggest that both miRNAs target the same set of genes with similar specificity. Nevertheless, anti-miR-33 oligonucleotides are expected to block the action of both miR-33a and miR-33b. 9 A limitation of our study is that the lack of rodent miR-33b prevents the direct translation of our results in Ldlr -/-mice to humans. Indeed, in marked contrast to our study, the longitudinal study in nonhuman primates did show a sustained elevation of HDL-c, as well as a decrease in TG. Whether the differences in cholesterol and TG metabolism 9 between mice and primates in response to anti-miR-33 treatment are due to miR-33b remains to be established. Such discrepancies between rodents and primates thus raise an important concern regarding the direct translation of data from rodent models to human physiology and metabolic disorders. Further studies using humanized mice, in which a miR-33b transgene is inserted within an intron of SREBF-1, will help us address this important question.
The mechanism behind the loss of elevated HDL-c in the anti-miR-33 group remains to be elucidated. It is likely that the potential atheroprotective effect of anti-miR-33-based therapies rely, at least in part, in their ability to promote and sustain such an increase in HDL-c. The fact that hepatic ABCA1 expression is still induced after 14 weekly anti-miR-33 injections suggests the existence of homeostatic compensatory mechanisms controlling plasma HDL. Interestingly, Brewer et al reported that hepatic overexpression of ABCA1 results in enhanced atherosclerosis in Ldlr -/-mice, 12 whereas van Eck et al showed that macrophage ABCA1 overexpression reduces atheromata in Ldlr -/-mice. 13 It is conceivable that the lack of atheroprotection in our model is the result of both proatherogenic and antiatherogenic effects that follow long-term silencing of miR-33 both in the liver and in macrophages in the lesion. Remarkably, Rayner et al showed that the expression of ABCA1 was induced in macrophages recovered from atheromata in 2'-fluoro-methoxyethyl anti-miR-33-treated mice. 7 Whether 2'F/MOE and locked nucleic acid oligonucleotides have different pharmacokinetic properties that result in distinctive bioavailability in plaques remains to be established. While this paper was under review, Horie et al reported that WD-fed miR-33/ApoE double knockout mice had decreased atheromata compared with ApoE -/-mice. 14 However, no significant changes in atherosclerotic lesion size were observed in ApoE -/-mice transplanted with miR-33/ApoE double knockout bone marrow, 14 suggesting that loss of miR-33 in bone marrow-derived cells is not atheroprotective per se. Interestingly, these double knockout mice also showed a tendency toward increased circulating TG, 14 although the changes did not reach statistical significance. Differences in the progression of atheromata after whole-body miR-33 deficiency or treatment with anti-miR-33 oligonucleotides are intriguing, and likely reflect the impact of miR-33 expression in several cell types (eg, hepatocytes, macrophages, endothelial, and smooth muscle cells). It is conceivable that anti-miR therapy could be effective in some, but not all, cell types where miR-33 is normally expressed. Tissue/cell-specific knockout mice for miR-33 will help us understand the relative contribution of hepatocyte and plaque (macrophage, endothelial, and smooth muscle cell) miR-33 to atherogenesis, and the antiatherogenic potential of anti-miR-33 oligonucleotides. It will also be important to establish whether different chemistries alter the bioavailability and potency of anti-miR-33 oligonucleotides in either liver or lesions.
